Royalty Pharma (RPRX) PT Raised to $67 at Morgan Stanley
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/8/2026
- S&P 500, Nasdaq end lower as crude prices jump, chip stocks weigh
- Oil rises 4% on revived Middle East worries, Hurricane Isaias supply disruption
- Chipotle, Starbucks shares volatile after report of potential takeover
- Why Citi says the Fed could be setting up for a dovish surprise
- Alphabet shares rise as Google pushes Gemini deeper into enterprise AI
Tweet
Share
E-mailGet Alerts RPRX Hot Sheet
Price: $56.21 -0.97%
Rating Summary:
12 Buy, 4 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 19 | Down: 21 | New: 62
Rating Summary:
12 Buy, 4 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 19 | Down: 21 | New: 62
Join SI Premium – FREE
Morgan Stanley analyst Terence Flynn raised the price target on Royalty Pharma (NASDAQ: RPRX) to $67.00 (from $65.00) while maintaining a Overweight rating.
You May Also Be Interested In
- Starbucks (SBUX) PT Lowered to $105 at UBS as Shares Already Reflect Improved Momentum
- Definity Financial Corp (DFY:CN) PT Lowered to Cdn$74 at UBS
- Freedom Broker Upgrades Constellation Brands (STZ) to Buy
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
